Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. New Life Medical Services, LLC
WARNING LETTER
•New Life Medical Services, LLC•May 20, 2024

New Life Medical Services, LLC – FDA Warning Letter, May 20, 2024

Record Details

The FDA issued a Warning Letter to New Life Medical Services, LLC, following an inspection conducted from May 14 to May 20, 2024. The agency found that the company is unlawfully selling several human-derived products, including Restor+, Regain, Renyte (from umbilical cord), ReCyte/Cytosomes (from amniotic fluid), and Rexo (an exosome product). These products are classified as unapproved new drugs and unlicensed biological products. The FDA determined that they are intended to diagnose, treat, or prevent diseases and affect body functions, based on company marketing materials. This violates Section 505(a) of the Federal Food, Drug, and Cosmetic Act and Section 351(a)(1) of the Public Health Service Act, which require premarket approval for such products. Furthermore, products like Restor+, Regain, and Renyte, which are human cells, tissues, or cellular or tissue-based products (HCT/Ps), fail to meet specific regulatory criteria under 21 CFR Part 1271. Specifically, they undergo more than "minimal manipulation" and are not intended for "homologous use," meaning their processing alters original characteristics and they are marketed for uses beyond their original function (e.g., healing/supplementing tissue, neuropathy, inflammation reduction, instead of acting as a conduit). Consequently, they are not exempt from drug and biologic regulations. The letter advises New Life Medical Services, LLC, that introducing these unapproved and unlicensed products into interstate commerce is prohibited, signaling the need for immediate corrective action to comply with federal law.

Company
New Life Medical Services, LLC
Inspection date
May 20, 2024
Product type
Other
Office
Center for Biologics Evaluation and Research
Person
  • Melissa J. Mendoza (Director)
View Company Profile

ID · db05600e-721b-4ac5-a12f-1b417f56c2e8

Violation Codes10
21.U.S.C. 355(a)21 U.S.C. 321(g)(1)21 CFR 1271.1521 CFR 1271.10(a)(2)FD&C Act 301(d)21 CFR 1271.3(d)21 CFR 1271.10(a)(1)21 CFR 1271.21021 U.S.C. 331(d)21 CFR 1271

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore New Life Medical Services, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.